Representative before the EPO

Employment test 51 - 200 employees
Company dna d young and co llp
operating since 1891
Headquarter in London and 2 offices
active in Legal Services, IP Consulting, and IP Portfolio Processing

Neil Jacob Nachshen has worked on the following 49 EPO patent applications which have been published in the last five years:

EP11714379

NOVEL COMBINATION AND USE

IPC classification:
A61K 31/351, A61K 31/4439, A61K 31/445, A61K 31/4709, A61P 23/02, A61P 31/00
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP11746287

COMBINATION OF A PYRROLOQUINOLINE COMPOUND AND A BETA-LACTAM ANTIMICROBIAL AGENT, MUPIROCIN OR CHLORHEXIDINE

IPC classification:
A61K 31/155, A61K 31/351, A61K 31/424, A61K 31/43, A61K 31/4745, A61K 31/7036, A61P 31/00, A61P 31/02, A61P 31/04, A61P 31/06
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP11745813

COMBINATION OF A PYRROLOQUINOLINE COMPOUND AND AN AMINOGLYCODISE ANTIMICROBIAL AGENT

IPC classification:
A61K 31/4745, A61K 31/70, A61K 31/7036, A61P 31/00, A61P 31/02, A61P 31/04, A61P 31/06
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP11773310

NOVEL COMPOSITION

IPC classification:
A61K 9/06, A61K 31/437, A61P 31/00, A61P 31/02, A61P 31/04
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP11804411

DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF

IPC classification:
A01N 43/42, A61K 31/47
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
APPLICATION WITHDRAWN
EP11813130

USE OF RASAGILINE FOR THE TREATMENT OF OLFACTORY DYSFUNCTION

IPC classification:
A61K 31/135, A61P 25/00, A61P 25/16
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP12757133

COMBINATION OF ANTI-CLUSTERIN OLIGONUCLEOTIDE WITH HSP90 INHIBITOR FOR THE TREATMENT OF PROSTATE CANCER

IPC classification:
A61K 31/4162, A61K 31/7088, A61P 35/00
Applicant:
The University of British Columbia
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP12757052

COMBINATION OF ANTI-CLUSTERIN OLIGONUCLEOTIDE WITH ANDROGEN RECEPTOR ANTAGONIST FOR THE TREATMENT OF PROSTATE CANCER

IPC classification:
A61K 31/4166, A61K 31/7088, A61P 5/28, A61P 35/00
Applicant:
The University of British Columbia
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP13176166

Rasagiline for parkinson's disease modification

IPC classification:
A01N 33/02, A61K 31/135, A61P 25/16
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP13166080

Low Frequency Glatiramer Acetate Therapy

IPC classification:
A61K 38/02, A61K 38/16, A61P 25/28
Applicant:
Yeda Research and Development Co. Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP11846599

USE OF LAQUINIMOD FOR REDUCING FATIGUE, IMPROVING FUNCTIONAL STATUS, AND IMPROVING QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS

IPC classification:
A61K 31/47, A61P 25/28
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP12817089

TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND GLATIRAMER ACETATE

IPC classification:
A01N 43/42, A61K 31/47
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP12755869

POLYMORPHIC FORM OF PRIDOPIDINE HYDROCHLORIDE

IPC classification:
A61K 31/445, A61P 25/28, C07D 211/24
Applicant:
Teva Pharmaceuticals International GmbH
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP12835589

ANTIBODIES AGAINST TL1A AND USES THEREOF

IPC classification:
A61K 39/395, A61P 29/00, C07K 16/24
Applicant:
Teva Pharmaceuticals Australia Pty Ltd
Agent:
Multiple attorneys, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP13187258

Stable laquinimod preparations

IPC classification:
A61K 31/438, A61K 31/47, C07D 209/34, C07D 209/42, C07D 471/10
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
PATENT GRANTED
EP12840164

ANTIBODIES TO CD1d

IPC classification:
A61K 39/395, A61P 1/16, A61P 9/10, A61P 11/06, A61P 17/06, A61P 43/00, C07K 16/28, C12N 5/10, C12N 15/13
Applicant:
Teva Pharmaceuticals Australia Pty Ltd
Agent:
Multiple attorneys, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP12840243

SINGLE NUCLEOTIDE POLYMORPHISMS USEFUL TO PREDICT CLINICAL RESPONSE FOR GLATIRAMER ACETATE

IPC classification:
A01N 37/12, C12Q 1/68
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP12840761

R(+)-N-METHYL-PROPARGYL-AMINOINDAN

IPC classification:
A61K 31/135
Applicant:
Teva Pharmaceuticals USA Inc
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP12840715

TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND FINGOLIMOD

IPC classification:
A61K 31/135, A61K 31/47
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP12775541

NOVEL PEPTIDES

IPC classification:
C07K 14/435
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP13153698

Crystals of Laquinimod Sodium, and Process for the Manufacture Thereof

IPC classification:
A61K 31/4704, C07D 215/22, C07D 215/54, C07D 215/56
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP13159275

Taxoid - Purification of Liquid Excipients

IPC classification:
A61K 9/00, A61K 47/10
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP12855452

THE HYDROBROMIDE SALT OF PRIDOPIDINE

IPC classification:
A61K 31/4453, A61P 25/28, C07D 211/00
Applicant:
Teva Pharmaceuticals International GmbH
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP12805898

TOFACITINIB SALTS

IPC classification:
A61K 31/519, A61P 35/00, C07D 487/04
Applicant:
Ratiopharm GmbH
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
PATENT GRANTED
EP12840538

RASAGILINE CITRAMIDE

IPC classification:
A61K 31/16
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13744015

USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNF THERAPY

IPC classification:
A01N 43/42, A61K 31/47
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP13749429

N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-QUINOLINE CARBOXAMIDE, PREPARATION AND USES THEREOF

IPC classification:
A61K 31/4704, C07D 215/56
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
APPLICATION WITHDRAWN
EP14181161

BChE albumin fusions for the treatment of cocaine abuse

IPC classification:
A61K 38/16, A61K 38/38, A61K 38/46, A61P 25/30
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14186019

Polymorphic form of imatinib mesylate and process for its preparation

IPC classification:
A61K 31/506, A61P 35/00, C07D 401/04
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13768294

TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND DIMETHYL FUMARATE

IPC classification:
A61K 31/4704
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP12817547

TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND INTERFERON-BETA

IPC classification:
A61K 31/47, A61K 31/4704, A61K 38/21, A61P 25/00
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP13784231

USE OF HIGH DOSE LAQUINIMOD FOR TREATING MULTIPLE SCLEROSIS

IPC classification:
A61K 31/47
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP13772325

PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY

IPC classification:
A61P 25/14
Applicant:
Teva Pharmaceuticals International GmbH
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION REQUESTED
EP13791341

METHOD FOR TREATING NON-SMALL CELL LUNG CANCER

IPC classification:
A61K 31/7105
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14185362

Tigecycline crystalline forms and processes for preparation thereof

IPC classification:
C07C 231/24, C07C 237/26
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
PATENT GRANTED
EP13816075

TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND FAMPRIDINE

IPC classification:
A01N 43/42, A01N 45/00, A61P 25/02
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP13816725

LAQUINIMOD FORMULATIONS WITHOUT ALKALIZING AGENT

IPC classification:
A61K 31/47
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP13740041

ORAL DOSAGE FORMS FOR MODIFIED RELEASE COMPRISING RUXOLITINIB

IPC classification:
A61K 9/20, A61K 9/48, A61K 31/4045, A61K 31/519
Applicant:
Ratiopharm GmbH
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP13829849

LAQUINIMOD FOR TREATMENT OF CANNABINOID RECEPTOR TYPE 1 (CB1) MEDIATED DISORDERS

IPC classification:
A61K 31/4704, A61P 25/02
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP13752800

PHARMACEUTICAL COMPOSITIONS OF MEMANTINE

IPC classification:
A61K 9/16, A61K 9/20, A61K 9/48, A61K 9/50, A61K 31/13
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
PATENT GRANTED
EP13829655

PARENTERAL FORMULATION OF RASAGILINE

IPC classification:
A61K 31/135, A61K 31/136, A61P 25/00
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP11757801

DEUTERATED ANALOGS OF PRIDOPIDINE USEFUL AS DOPAMINERGIC STABILIZERS

IPC classification:
A61K 31/445, A61P 25/00, C07B 59/00, C07D 211/24
Applicant:
Teva Pharmaceuticals International GmbH
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP13840841

LAQUINIMOD AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS

IPC classification:
A61P 25/00, A61P 25/18, A61P 25/28
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION REQUESTED
EP11813128

DISPERSIONS OF RASAGILINE CITRATE

IPC classification:
A61K 9/16, A61K 31/135
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11804416

5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF

IPC classification:
A61K 31/47, A61K 31/497
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
APPLICATION WITHDRAWN
EP11751300

TREATMENT OF RHEUMATOID ARTHRITIS WITH A COMBINATION OF LAQUINIMOD AND METHOTREXATE

IPC classification:
A61K 31/4704, A61K 31/519, A61P 19/02
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11833199

CYTOKINE BIOMARKERS AS PREDICTIVE BIOMARKERS OF CLINICAL RESPONSE FOR GLATIRAMER ACETATE

IPC classification:
A61K 9/00, A61K 31/785, A61K 38/07, C07K 14/52, G01N 33/68
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
PATENT GRANTED
EP11751305

TREATMENT OF LUPUS ARTHRITIS USING LAQUINIMOD

IPC classification:
A61K 31/4704, A61K 45/06, A61P 19/02, A61P 37/06
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
PATENT GRANTED
EP11751295

TREATMENT OF LUPUS NEPHRITIS USING LAQUINIMOD

IPC classification:
A61K 31/47, A61K 31/4704, A61K 31/5355, A61K 31/573, A61P 37/00
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT

Please Sign in to use this feature